903886-81-7

Basic information

• Product Name: N-[1-Methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynyl]acetamide
• Synonyms: N-[1-Methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynyl]acetamide
• CAS NO: 903886-81-7
• Molecular Formula: C21H18N2O3S
• Molecular Weight: 378.44
• Mol File: 903886-81-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.30
• Refractive Index: 1.643
• CAS DataBase Reference: N-[1-Methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[1-Methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynyl]acetamide(903886-81-7)
• EPA Substance Registry System: N-[1-Methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynyl]acetamide(903886-81-7)

Safety Data

• Hazardous Substances Data: 903886-81-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C21H18N2O3S/c1-15(23-16(2)24)8-13-20-14-22-21(27-20)26-19-11-9-18(10-12-19)25-17-6-4-3-5-7-17/h3-7,9-12,14-15H,1-2H3,(H,23,24)

Upstream product

• 42105-25-9 N-(1-methyl-prop-2-ynyl)acetamide 
• 904962-08-9 2-{1-methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynyl}-1H-isoindole-1,3(2H)-dione 
• 903886-77-1 5-iodo-2-(4-phenoxyphenoxy)thiazole 
• 903886-76-0 2-(4-phenoxyphenoxy)thiazole 
• 831-82-3 4-Phenoxyphenol 
• 903886-91-9 1-methyl-3-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]prop-2-ynylamine 
• 108-24-7 acetic anhydride 

Relevant articles and documents

Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome

The present invention relates to compounds of formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy) thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors

A structurally novel acetyl-CoA carboxylase (ACC) inhibitor is identified from high-throughput screening. A preliminary structure-activity relationship study led to the discovery of potent dual ACC1/ACC2 and ACC2 selective inhibitors against human recombinant ACC1 and ACC2. Selective ACC2 inhibitors exhibited IC50 1000-fold selectivity against ACC1. (S)-Enantiomer 9p exhibited high ACC2 activity and lowered muscle malonyl-CoA dose-dependently in acute rodent studies, whereas (R)-enantiomer 9o was weak and had no effect on the malonyl-CoA level.